NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.

Biomarkers, Tumor Carcinoma, Non-Small-Cell Lung / diagnosis Humans Immunotherapy Lung Neoplasms / diagnosis

Journal

Journal of the National Comprehensive Cancer Network : JNCCN
ISSN: 1540-1413
Titre abrégé: J Natl Compr Canc Netw
Pays: United States
ID NLM: 101162515

Informations de publication

Date de publication:
02 03 2021
Historique:
entrez: 5 3 2021
pubmed: 6 3 2021
medline: 6 11 2021
Statut: epublish

Résumé

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.

Identifiants

DOI: 10.6004/jnccn.2021.0013 PMID: 33668021
pubmed: 33668021
doi: 10.6004/jnccn.2021.0013
pii: jnccnGLINS1903
doi:
pii:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Practice Guideline Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

254-266

Auteurs

David S Ettinger (DS)

1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Douglas E Wood (DE)

2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

Dara L Aisner (DL)

3University of Colorado Cancer Center.

Wallace Akerley (W)

4Huntsman Cancer Institute at the University of Utah.

Jessica R Bauman (JR)

5Fox Chase Cancer Center.

Ankit Bharat (A)

6Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Debora S Bruno (DS)

7Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.

Joe Y Chang (JY)

8The University of Texas MD Anderson Cancer Center.

Lucian R Chirieac (LR)

9Dana-Farber/Brigham and Women's Cancer Center.

Thomas A D'Amico (TA)

10Duke Cancer Institute.

Thomas J Dilling (TJ)

11Moffitt Cancer Center.

Jonathan Dowell (J)

12UT Southwestern Simmons Comprehensive Cancer Center.

Scott Gettinger (S)

13Yale Cancer Center/Smilow Cancer Hospital.

Matthew A Gubens (MA)

14UCSF Helen Diller Family Comprehensive Cancer Center.

Aparna Hegde (A)

15O'Neal Comprehensive Cancer Center at UAB.

Mark Hennon (M)

16Roswell Park Comprehensive Cancer Center.

Rudy P Lackner (RP)

17Fred & Pamela Buffett Cancer Center.

Michael Lanuti (M)

18Massachusetts General Hospital Cancer Center.

Ticiana A Leal (TA)

19University of Wisconsin Carbone Cancer Center.

Jules Lin (J)

20University of Michigan Rogel Cancer Center.

Billy W Loo (BW)

21Stanford Cancer Institute.

Christine M Lovly (CM)

22Vanderbilt-Ingram Cancer Center.

Renato G Martins (RG)

2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

Erminia Massarelli (E)

23City of Hope National Medical Center.

Daniel Morgensztern (D)

24Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

Thomas Ng (T)

25The University of Tennessee Health Science Center.

Gregory A Otterson (GA)

26The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

Sandip P Patel (SP)

27UC San Diego Moores Cancer Center.

Gregory J Riely (GJ)

28Memorial Sloan Kettering Cancer Center.

Steven E Schild (SE)

29Mayo Clinic Cancer Center.

Theresa A Shapiro (TA)

1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Aditi P Singh (AP)

30Abramson Cancer Center at the University of Pennsylvania.

James Stevenson (J)

7Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.

Alda Tam (A)

8The University of Texas MD Anderson Cancer Center.

Jane Yanagawa (J)

31UCLA Jonsson Comprehensive Cancer Center; and.

Stephen C Yang (SC)

1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Kristina M Gregory (KM)

32National Comprehensive Cancer Network.

Miranda Hughes (M)

32National Comprehensive Cancer Network.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › NCCN Guidelines Insights: Non-Small Cell Lung...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › NCCN Guidelines Insights: Non-Small Cell Lung...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › NCCN Guidelines Insights: Non-Small Cell Lung...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › NCCN Guidelines Insights: Non-Small Cell Lung...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › NCCN Guidelines Insights: Non-Small Cell Lung...